Hypothesis

Inter‑omics discordance—specifically, a divergence where epigenetic age indicates younger biological state while proteomic age indicates older state—reflects organ‑specific accumulation of senescence‑associated secretory phenotype (SASP) proteins that are not captured by DNA methylation clocks, a limitation noted in multi-omics integration approaches 1. We hypothesize that this epigenetic‑proteomic age gap predicts imminent functional decline in the organ system contributing the majority of the discordant proteomic signal, and that targeted reduction of SASP (e.g., via senolytics or NAD⁺ boosters) will narrow the gap and delay clinical frailty.

Mechanistic Rationale

Epigenetic clocks primarily measure cell‑intrinsic chromatin modifications that change slowly and are relatively resistant to acute extracellular fluctuations. In contrast, plasma proteomic clocks are highly responsive to secreted factors, including SASP cytokines, chemokines, and matrix remodelers that surge when tissue‑resident senescent cells expand. When a tissue undergoes stress‑induced senescence, its epigenome may not yet have accrued the methylation changes needed to shift the epigenetic clock, while the secretome rapidly alters the proteomic clock, producing a younger epigenetic readout alongside an older proteomic readout. This mismatch therefore serves as an early warning of tissue‑specific frailty before global epigenetic aging catches up. Such tissue‑specific signatures have been missed in prior digital twin models that achieved high accuracy for risk prediction but lower for therapy tailoring 2.

Testable Predictions

1. In a longitudinal cohort of adults aged 60‑80, baseline epigenetic age (Horvath2013) and proteomic age (Lehallier plasma proteome clock) will be quantified every 3 months for 2 years. Individuals whose proteomic age exceeds epigenetic age by > 4 years (discordance threshold) will show a 2‑fold higher incidence of clinically significant organ‑specific events (e.g., reduced gait speed, increased hospitalizations for cardiovascular or pulmonary causes) within the following 12 months compared with concordant or oppositely discordant peers. Cohort recruitment will stratify by education and income to mitigate known demographic biases in digital twin performance 5.

2. Administering a senolytic regimen (dasatinib + quercetin) or NAD⁺ precursor (nicotinamide riboside) to the high‑discordance subgroup for 6 months will significantly reduce the proteomic‑epigenetic age gap (mean reduction ≥ 2 years) without altering epigenetic age alone, as measured at 3‑ and 6‑month intervals.

3. Reduction of the age gap will mediate improvements in organ‑specific functional outcomes (e.g., 6‑minute walk distance, FEV1) independent of changes in chronological age or comorbid burden.

Falsifiability

If high discordance fails to predict organ‑specific events, or if senolytic/NAD⁺ supplementation does not narrow the proteomic‑epigenetic gap despite adequate target engagement (verified by plasma SASP reduction), the hypothesis is falsified. Likewise, if gap reduction occurs without functional benefit, the causal link between discordance and frailty would be refuted. Validation could leverage synthetic control groups as demonstrated in Alzheimer’s trials 3.

Implications for Digital Twins

Integrating discordance metrics into digital twin frameworks would allow the model to flag emerging tissue‑specific risk that epigenetic‑only clocks miss, prompting personalized interventions (e.g., localized senolytic delivery) before irreversible damage. This addresses the open question of handling inter‑omics discordance by turning it into actionable predictive information, and could be implemented on regulatory‑grade platforms meeting GxP, 21 CFR Part 11, and SOC 2 Type 2 standards 4.